Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?
World Journal of Surgical Oncology, 2010 Introduction Prediction of optimal cytoreduction in patients with advanced epithelial ovarian caner preoperatively. Methods Patients with advanced epithelial ovarian cancer who underwent surgery for the first time from Jan.
Behtash Nadereh +5 more
doaj +1 more source
Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer [PDF]
Obstetrics & Gynecology Science, 2020 ObjectiveEpithelial ovarian cancer (EOC) requires an aggressive surgical approach. The important part of literature on ovarian cancer surgery emphasize residual tumor and survival analyses. Morbidity issue keeps in background.
Emre Günakan +5 more
doaj +1 more source
Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]
, 2015 BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio +8 more
core +2 more sources
Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]
, 2019 Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica +8 more
core +1 more source
Acta Medica Lituanica, 2014 Background. Diaphragmatic peritoneal metastasis by advanced epithelial ovarian cancer is a very common holdback precluding optimal cytoreduction.
Tomas Lūža +2 more
doaj +1 more source
CLINICAL CASE OF MULTIMODALITY TREATMENT OF METASTATIC BLADDER CANCER
Сибирский онкологический журнал, 2020 Background. Bladder cancer is one of the most common cancers. Non-muscle-invasive bladder cancer is characterized by the high frequency of recurrence after radical treatment (up to 50–60 %), and muscle-invasive bladder cancer has a lower recurrence rate (
A. V. Lykov +3 more
doaj +1 more source
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial [PDF]
, 2016 Vaccination with priming and expansion of tumour reacting T cells is an important therapeutic option to be used in combination with novel checkpoint inhibitors to increase the specificity of the T cell infiltrate and the efficacy of the treatment. In
Antonilli M +13 more
core +1 more source
Frontiers in Neurology, 2017 BackgroundUnlike many other central nervous system (CNS) tumors, the surgical management of primary central nervous system lymphomas (PCNSL) is traditionally limited by diagnostic biopsy.
Jonathan Yun +9 more
doaj +1 more source
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
Research and Practice in Thrombosis and Haemostasis, 2022 A state‐of‐the‐art lecture titled “Myeloproliferative Neoplasm‐associated Thrombosis” was presented at the ISTH congress in 2021. We summarize here the main points of the lecture with two purposes: to report the incidence rates of major thrombosis in ...
Tiziano Barbui +2 more
doaj +1 more source
Clinical and Experimental Obstetrics & Gynecology, 2022 Background: Tumor morcellation happened to facilitate iatrogenic metastasis for patients with occult uterine sarcoma. The optimal completion surgery for these patients needed to be established.
Chao Ding, Jianqing Zhu
doaj +1 more source